- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
December 27th, 2005
Jack Uldrich: Late last week, Westaim Corp (Nasdaq: WEDX) priced the IPO of 4.5 million shares of its subsidiary, Nucryst Pharmaceuticals (Nasdaq: NCST), at $10 a share -- well below the forecast price of $12 to $14.
Although Nucryst is a legitimate nanotech company and its IPO deserves to be taken seriously, investors should proceed with great caution because they risk getting burned.
|Related News Press|
Nanometrics Announces Upcoming Investor Events July 20th, 2016
The NanoWizard® AFM from JPK is applied for interdisciplinary research at the University of South Australia for applications including smart wound healing and how plants can protect themselves from toxins July 26th, 2016
Accurate design of large icosahedral protein nanocages pushes bioengineering boundaries: Scientists used computational methods to build ten large, two-component, co-assembling icosahedral protein complexes the size of small virus coats July 25th, 2016
Russia’s Nano-enabled Products Market to Witness Massive Growth February 8th, 2011
Adept Technology Announces Orders for Over $600K from Chinese Partner January 18th, 2011
Nanostart-held ItN Nanovation Receives Major Follow-on Order in Saudi Arabia November 29th, 2010
Homegrown Companies Developing Batteries for Clean Energy Storage November 2nd, 2010